[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"women39s-health\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:women39s-health":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,46,76,118],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":4},"100606532","effect-of-semiconductor-embedded-wearable-sleeve-on-treatment-of-primary-dysmenorrhea-symptoms-100606532",false,"NCT07176780","Effect of Semiconductor Embedded Wearable Sleeve on Treatment of Primary Dysmenorrhea Symptoms","Effect of Semiconductor Embedded Wearable Sleeve on the Treatment and Mitigation of Primary Dysmenorrhea Symptoms: A Randomized, Double-Blinded, Placebo-Controlled Clinical Trial","Inclusion Criteria:\n\n* Self-reported primary dysmenorrhea during past three menstrual cycles\n* Age 18-45 inclusive at the time of consent\n* Self-reported typical primary dysmenorrhea symptom pain greater than 4 on a 1-10 visual analog scale (VAS)\n* History of regular menstrual cycles with a usual length of 21 to 35 days\n* Willing and able to provide informed consent and adhere to study requirements\n\nExclusion Criteria:\n\n* History of neurological conditions, including multiple sclerosis or Parkinson's disease\n* Secondary dysmenorrhea including confirmed or suspected endometriosis or fibroids or intrauterine device\n* Self-reported size not available in study device\n* Pregnant or planning to become pregnant during the study\n* Have within the past six months of enrollment, or are planning to in the next six months, start or discontinue any of the following contraceptive methods:\n\n  1. intrauterine device\n  2. oral contraceptives,\n  3. contraceptive patch,\n  4. implant (Nexplanon),\n  5. shot (Depo-Provera),\n  6. vaginal ring\n* Chronic pain conditions unrelated to primary dysmenorrhea\n* Auto-immune or auto-inflammatory diseases\n* Has used within the last 90 days or is planning to use nicotine-containing products\n* History of metabolic disorders\n* Active infection (local or systemic) that, in the opinion of the investigator, would prevent usage of the device\n* In the opinion of the investigator, any other criteria or condition that could increase the risk associated with study participation or study treatment or could interfere with the interpretation of study results\n* Have taken any investigational drug or used any investigational device within the 30 days prior to consent.",true,"FEMALE","18 Years","45 Years",{"count":21,"type":22},100,"ESTIMATED","INTERVENTIONAL",[25],"NA","This study is looking to test a non-compressive semiconductor embedded body sleeve for treatment of primary dysmenorrhea symptoms. Dysmenorrhea is the lower abdominal pain (sometimes referred to as \"cramping\") experienced during menstruation (monthly \"period\"), affecting up to 94% of people aged from 10-20 years old. The semiconductor embedded fabric increases blood circulation through activation of the embedded elements with body heat while worn and releases energy waves as well as negative ions. This energy has an effect inside the body that increases oxygen and nutrient flow to tissues, and can help to decrease pain and inflammation. This study is testing this technology to see if it can be used as a non-pharmacological treatment for menstrual cramping.",[28,29,30,31],"Primary Dysmenorrhea","Primary Dysmenorrhea (PD)","Menstrual Cramps","Women's Health",[30,33,28,31],"Dysmenorrhea","NOT_YET_RECRUITING","2026-06-12",{"date":37,"type":38},"2026-06-16","ACTUAL",{"date":40,"type":22},"2026-12",{"date":42,"type":22},"2027-03",{"name":44,"class":45},"University of California, Davis","OTHER",{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":23,"phases":55,"briefSummary":56,"conditions":57,"keywords":61,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":75},"100594241","anxiety-physiological-parameters-patient-satisfaction-and-vr-in-gynecological-oncology-surgery-100594241","NCT07016880","Anxiety, Physiological Parameters, Patient Satisfaction and VR in Gynecological Oncology Surgery","The Effect of Virtual Reality Intervention on Preoperative Anxiety, Physiological Parameters and Patient Satisfaction in Women Scheduled for Gynecological Oncology Surgery: A Randomised Controlled Trial","Inclusion Criteria:\n\n* The participant must have a confirmed diagnosis of gynecological cancer.\n* The participant must be aware of their gynecological cancer diagnosis.\n* Participants must be 18 years of age or older.\n* Verbal and written informed consent to participate in the study must be obtained.\n* The participant must be able to communicate verbally and in writing in Turkish.\n* No communication impairments (e.g., visual, auditory, or cognitive) should be present.\n* This must be the participant's first surgical intervention related to gynecological oncology.\n* Eastern Cooperative Oncology Group (ECOG) Performance Status must not exceed 2.\n* The planned surgical procedure must be a laparotomy.\n\nExclusion Criteria:\n\n* History of recurrent gynecological cancer.\n* Presence of vision problems that prevent the use of VR goggles, including participants who wear glasses or have uncorrected vision impairment.\n* Presence of conditions such as migraines, vertigo, active nausea, vomiting, or frequent headaches.\n* Sensitivity to motion sickness.\n* Diagnosis of a psychiatric condition, whether under pharmacological or non-pharmacological treatment.\n* Withdrawal of consent during the study.\n* Removal of the virtual reality headset during the intervention.\n* Development of any medical complications during the intervention period.",{"count":54,"type":22},66,[25],"Surgical procedures often cause significant anxiety in patients, particularly among women undergoing gynecological oncology surgeries. Preoperative anxiety is a common and preventable condition that can negatively affect both physiological parameters and the overall surgical experience. It may lead to increased heart rate, elevated blood pressure, respiratory distress, and psychological discomfort, increasing the risk of complications during and after surgery. Women facing gynecological cancer surgery often experience heightened anxiety due to concerns about survival, loss of reproductive organs, body image changes, and sexual health.\n\nVirtual reality (VR) has emerged as a promising non-pharmacological approach for reducing preoperative anxiety. By immersing patients in a calming virtual environment that engages visual and auditory senses, VR helps promote relaxation, reduce stress, and enhance the patient's sense of control before surgery. It is safe, easy to implement, cost-effective, and does not have the side effects associated with medications.\n\nAlthough VR has demonstrated effectiveness in reducing anxiety in various surgical contexts-including orthopedic, colorectal, and minor gynecological procedures-its impact in gynecologic oncology surgery remains underexplored. This randomized controlled trial aims to evaluate the effect of a VR intervention on preoperative anxiety, physiological parameters (blood pressure, heart rate, respiratory rate, oxygen saturation), and patient satisfaction in women scheduled for gynecologic oncology surgery.\n\nParticipants will be randomly assigned to either the intervention group (receiving VR) or the control group (receiving standard care). Anxiety and physiological measures will be evaluated before and after the respective intervention in both groups. Patient satisfaction will be assessed once, immediately after the intervention and before surgery.\n\nThe primary objective is to assess whether VR effectively reduces preoperative anxiety and stabilizes physiological indicators. The secondary objective is to evaluate patient satisfaction with the preoperative experience. This study will contribute to the evidence base for using VR as a nursing-led, non-invasive strategy to enhance surgical care in gynecologic oncology.",[58,31,59,60],"Preoperative Anxiety","Gynecological Cancers","Gynecological Surgery",[60,62,58,63,64],"Gynecological Oncology","Preoperative Anxiety Management","Virtual Reality","RECRUITING","2025-09-09",{"date":68,"type":38},"2025-09-10",{"date":70,"type":38},"2025-07-15",{"date":72,"type":22},"2026-07-15",{"name":74,"class":45},"Hacettepe University",1,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":16,"sex":82,"minAge":18,"maxAge":4,"enrollmentInfo":83,"targetDuration":85,"studyType":86,"phases":4,"briefSummary":87,"conditions":88,"keywords":101,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":117},"100589754","apple-health-study-100589754","NCT06958523","Apple Health Study","Inclusion Criteria:\n\n* Be at least 18 years old (at least 19 years old in Alabama and Nebraska, at least 21 years old in Puerto Rico);\n* Live in the United States of America;\n* Have an iPhone;\n* Have installed Apple Research app on your iPhone;\n* Be comfortable communicating in written and spoken English;\n* Be willing and able to provide informed consent to participate in the Study.\n\nExclusion Criteria:\n\n* Share your iCloud account, iPhone, or devices that collect health data such as Apple Watch with anyone else, because it could result in sharing another person's health information with the Study, making it challenging for researchers to use your information.","ALL",{"count":84,"type":22},500000,"5 Years","OBSERVATIONAL","The Apple Health Study aims to build a diverse and inclusive group of participants to help researchers advance our understanding of how signals and information collected from apps and devices relate to health and may be used to predict, detect, monitor, and manage changes in health.\n\nTo enroll, US residents who have an iPhone can download the Apple Research app from the App Store and go through the introduction and informed consent for the Apple Health Study. This study is fully remote, and all are invited to enroll if the eligibility criteria are met.\n\nParticipants will be asked to complete tasks and surveys, using their iPhone and Apple Research app which include:\n\n* Selecting the types of data they would like to share with the study such as health and sensor data\n* Completing tasks and surveys including areas such as personal demographic information, personal medical history, family history, and social determinants of health",[89,90,91,92,93,94,95,96,97,98,99,100,31],"Mental Health","Sleep","Exercise","Hormones","Metabolic Health","Hearing","Aging","Lifestyle Factors","Functional Capacity","Neurological Conditions","General Health","Wellbeing",[80,102,103,104,105,106],"Large Scale Digital Study","Digital Biomarkers","Research App","Apple Research App","iPhone","2025-07-24",{"date":109,"type":38},"2025-07-29",{"date":111,"type":38},"2025-02-12",{"date":113,"type":22},"2030-02",{"name":115,"class":116},"Apple Inc.","INDUSTRY",2,{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":124,"eligibilityCriteria":125,"healthyVolunteers":11,"sex":82,"minAge":18,"maxAge":4,"enrollmentInfo":126,"targetDuration":4,"studyType":23,"phases":128,"briefSummary":129,"conditions":130,"keywords":135,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":75},"100595885","patient-centered-personalized-cardiac-rehabilitation-in-post-acute-coronary-syndrome-break-trial-100595885","NCT07038265","Patient-centered Personalized Cardiac Rehabilitation in Post Acute Coronary Syndrome (BREAK-trial)","Patient-centered Cardiac rehaBilitation pRogramE in Post Acute Coronary Syndrome:Identification of Key Barriers and Evaluation of Personalized Intervention (BREAK-trial)","BREAK","Inclusion Criteria:\n\n1. Patient aged ≥ 18 years\n2. Patients discharged within the last 30 days after an admission for ACS or in the discharge planning process for an admission for ACS.\n3. The patient is able to fully communicate with the research team and comply with all study procedures.\n4. The patient voluntarily signs and dates the informed consent form approved by the ethics committee\n\nExclusion Criteria:\n\n1. Age \\\u003C18 years\n2. Participation in another clinical trial\n3. Moderate or severe cognitive impairment in the absence of a competent caregiver\n4. Absence of social support\n5. Institutionalized patient\n6. Life expectancy \\\u003C1 year\n7. Candidates for end-of-life care\n8. Severe psychiatric illness\n9. Planned cardiac surgery including transplant or circulatory support implant\n10. Death before hospital discharge in patients included in the hospital discharge planning phase\n11. Carrier of heart transplant.\n12. Patient unable or refusing to give written informed consent to participate\n13. Patients who, in the opinion of the investigator, are unsuitable candidates for the study",{"count":127,"type":22},202,[25],"The primary objective of this study is to compare an integrated, multidisciplinar patient-centered CRP (Cardiac Rehabilitation Program) (intervention group) especially focused on covering the needs for the female and fragile population to the usual care conventional CRP (control group)",[131,132,133,134,31],"Acute Coronary Syndromes (ACS)","Cardiac Rehabilitation","Frailty","Women",[136,137,138,139,140,141,142],"frailty","sarcopenia","cardiac rehabilitation","gender perspective","acute coronary syndrome","coronary artery disease","patient-centered care","2025-06-17",{"date":145,"type":38},"2025-06-26",{"date":147,"type":38},"2025-05-26",{"date":149,"type":22},"2027-11",{"name":151,"class":45},"Institut d'Investigació Biomèdica de Bellvitge"]